Anticipating a rising need for individually wrapped vial medication manufacturing, The Ritedose Corporation, Inc. (Ritedose) is adding a seventh Syntegon packaging line to its state-of-the-art manufacturing facility that will double the company¡¯s capacity.
Ritedose is the largest CDMO in the United States specializing in sterile Blow-Fill-Seal (BFS) production of unit dose solutions for the ophthalmic and respiratory markets. The new line will be operated by a team of highly skilled professionals committed to Ritedose¡¯s excellence in sterile manufacturing.
The new Syntegon packaging system doubles Ritedose¡¯s capacity to deliver individually wrapped vial medications to patients. The packaging line will be able to process between 160 million and 170 million vials annually. By increasing efficiency and flexibility, Ritedose is poised to expand its packaging options to better serve the evolving needs of its customers.
The Syntegon Packaging line will support Ritedose¡¯s manufacturing efforts for Verona Pharma plc¡¯s Ohtuvayre, a new novel product for Chronic Obstructive Pulmonary Disease (COPD). Ohtuvayre, an innovative first-in-class PDE3 and PDE4 inhibitor, is the first inhaled product with a novel mechanism of action approved in more than 20 years. In September 2024, Ritedose announced it is the manufacturing partner of choice for Verona. In addition to Ohtuvayre, the additional packing line enables Ritedose to meet individually wrapped vial packaging needs for other disease states.
¡°At Ritedose, we make significant investments to support our expanding manufacturing efforts. This summer we expanded our sterile Blow-Fill-Seal (BFS) capabilities by an additional 180-million-unit dose capacity for ophthalmic and respiratory medications. These investments underscore our commitment to meeting the demands for high-quality, sterile unit dose solutions. Our seventh Syntegon packaging line will greatly enhance our ability to serve Verona Pharma and future clients,¡± Ritedose President and Chief Executive Officer Jody Chastain said.
For more than 20 years, Ritedose has relied on Syntegon Technology, a leader in processing and packaging, to deliver reliable, innovative solutions for its pharmaceutical products.
This latest addition¡ªdesigned for automated secondary packaging of pharmaceutical and consumer goods¡ªreinforces Ritedose¡¯s commitment to patient safety and quality. Created specifically for individually wrapped vial medications, the system maximizes output while drastically reducing waste.
Ritedose expects the packaging line to be in service by early summer of 2025. The automated system is currently undergoing Site Acceptance Testing at The Ritedose facility.
read more
Asthma and COPD Drug Market report published by Value Market Research, which studies the future outlook of the market.
It includes the size, share, growth, trends, key players, segments and regional analysis in detail during the study year 2020-2027.The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide.
The major players in the asthma and copd drug market market include Mylan, Aerovance Inc. Alkermes Inc. Almirall SA.
Genentech Inc. Sepracor, Inc. Skyepharma plc.
This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.Get more information on "Global Asthma and COPD Drug Market Research Report" by requesting FREE Sample Copy at https://www.valuemarketresearch.com/contact/asthma-and-copd-drug-market/download-sampleMarket DynamicsThe advancement in the medical sciences and technology and the heavy investment of the giant drug and pharmaceutical companies have been producing pioneer therapies and drugs for treating asthma and COPD since the late twentieth century.
High prevalence of asthma and COPD, generation of innovative medicines and their approval by the Food and Drug Administration (FDA), and massive patients of asthma and COPD receiving the treatment accelerate the growth of the drug markets.